Brief: BriaCell Announces Positive End Of Phase II Meeting With The FDA
18/01/2023 14:46
Jan 18 (Reuters) - Briacell Therapeutics Corp BCT.TO :
* BRIACELL ANNOUNCES POSITIVE END OF PHASE II MEETING WITH
THE FDA
FOR BRIA-IMT™ COMBINATION IN ADVANCED METASTATIC BREAST CANCER
* BRIACELL THERAPEUTICS : FDA AGREED ON PRIMARY END POINT,
ESSENTIAL ELEMENTS OF PIVOTAL REGISTRATION STUDY DESIGN, AND
TYPE OF PATIENTS TO BE INCLUDED
* BRIACELL THERAPEUTICS CORP - AFTER REVIEWING BRIACELL'S
FAST
TRACK DESIGNATED PHASE I/IIA DATA, FDA HAS AGREED ON PRIMARY END
POINT
Source text for Eikon: ID:nGNX1VmgTr
Further company coverage: BCT.TO
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study